CY1114724T1 - Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων - Google Patents
Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτωνInfo
- Publication number
- CY1114724T1 CY1114724T1 CY20131101003T CY131101003T CY1114724T1 CY 1114724 T1 CY1114724 T1 CY 1114724T1 CY 20131101003 T CY20131101003 T CY 20131101003T CY 131101003 T CY131101003 T CY 131101003T CY 1114724 T1 CY1114724 T1 CY 1114724T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- elastase proteins
- reconstructioned
- proteins
- industrial construction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21036—Pancreatic elastase (3.4.21.36)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε μεθόδους για την βιομηχανική κατασκευή, καθαρισμό, συνταγοποίηση και χρήση βιολογικώς δραστικών ανασυνδυασμένων πρωτεϊνών ελαστάσης. Περιγράφονται μέθοδοι ανασυνδυασμού για παραγωγή θεραπευτικώς χρήσιμων πρωτεϊνών ελαστάσης, καθώς επίσης φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω πρωτεΐνες ελαστάσης. Επίσης αποκαλύπτονται νέες ανασυνδυασμένες πρωτεΐνες ελαστάσης και παρασκευάσματα πρωτεΐνης. Περιγράφονται μέθοδοι για θεραπεία και αποτροπή ασθενειών βιολογικών αγωγών χρησιμοποιώντας φαρμακευτικές συνθέσεις που περιέχουν τις πρωτεΐνες ελαστάσης της εφεύρεσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99231907P | 2007-12-04 | 2007-12-04 | |
US12/327,809 US8501449B2 (en) | 2007-12-04 | 2008-12-03 | Recombinant elastase proteins and methods of manufacturing and use thereof |
EP08861467.2A EP2229440B9 (en) | 2007-12-04 | 2008-12-04 | Recombinant elastase proteins and methods of manufacturing and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114724T1 true CY1114724T1 (el) | 2016-10-05 |
Family
ID=40344763
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101003T CY1114724T1 (el) | 2007-12-04 | 2013-11-12 | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων |
CY20171100583T CY1118930T1 (el) | 2007-12-04 | 2017-06-02 | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100583T CY1118930T1 (el) | 2007-12-04 | 2017-06-02 | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων |
Country Status (26)
Country | Link |
---|---|
US (14) | US8501449B2 (el) |
EP (3) | EP2666854B1 (el) |
JP (3) | JP5829808B2 (el) |
KR (3) | KR101824350B1 (el) |
CN (4) | CN109893647A (el) |
AR (1) | AR069584A1 (el) |
AU (1) | AU2008338743B2 (el) |
BR (1) | BRPI0819977A2 (el) |
CA (1) | CA2707051C (el) |
CY (2) | CY1114724T1 (el) |
DK (2) | DK2229440T3 (el) |
ES (2) | ES2627066T3 (el) |
HK (1) | HK1148772A1 (el) |
HR (2) | HRP20131135T1 (el) |
HU (1) | HUE032739T2 (el) |
IL (2) | IL206157A (el) |
LT (1) | LT2666854T (el) |
MX (2) | MX2010006211A (el) |
NZ (2) | NZ585866A (el) |
PL (2) | PL2229440T3 (el) |
PT (2) | PT2229440E (el) |
RS (2) | RS55982B1 (el) |
RU (1) | RU2611200C2 (el) |
SI (2) | SI2666854T1 (el) |
TW (2) | TWI577385B (el) |
WO (1) | WO2009079220A2 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501449B2 (en) * | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
CN102250863B (zh) * | 2011-04-29 | 2012-12-05 | 天津金斯坦生物科技有限公司 | 基因重组人中性粒细胞弹性蛋白酶及其制备方法和该弹性蛋白酶的医药用途 |
US10202630B2 (en) * | 2013-03-15 | 2019-02-12 | Alderbio Holdings Llc | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells |
CA2905180C (en) | 2013-03-15 | 2023-03-07 | Alder Biopharmaceuticals, Inc. | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells |
KR20240005134A (ko) * | 2017-03-10 | 2024-01-11 | 볼트 쓰레즈, 인크. | 재조합 단백질을 고분비 수율로 생산하기 위한 조성물 및 방법 |
EP4065167A4 (en) * | 2019-11-26 | 2024-03-27 | Childrens Hospital Med Ct | INHIBITION OF CELA-1 FOR THE TREATMENT OF PULMONARY DISEASE |
WO2021146233A1 (en) * | 2020-01-14 | 2021-07-22 | Basf Se | Method for producing recombinant protein in yeast cells |
KR20230054355A (ko) * | 2020-08-18 | 2023-04-24 | 온칠리스 파마 인코포레이티드 | 변형된 돼지 췌장 엘라스타아제 단백질 |
JP2023545347A (ja) * | 2020-08-18 | 2023-10-30 | オンチレス・ファーマ・インコーポレイテッド | 改変セリンプロテアーゼプロタンパク質 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2508408A (en) | 1943-10-11 | 1950-05-23 | Sidney H Liebson | Averaging indicator |
US2546308A (en) | 1948-12-29 | 1951-03-27 | Kahler John | Floor marking device |
US5212068A (en) * | 1985-04-05 | 1993-05-18 | Sankyo Company Limited | Human pancreatic elastase |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
JPH0673456B2 (ja) | 1986-04-26 | 1994-09-21 | 三共株式会社 | ヒト・膵臓エラスタ−ゼ▲i▼ |
US5162205A (en) | 1986-04-26 | 1992-11-10 | Sankyo Company, Limited | Human pancreatic elastase I |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5543302A (en) | 1988-05-27 | 1996-08-06 | Solvay Enzymes, Inc. | Proteases of altered stability to autolytic degradation |
DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
DK0452484T3 (da) | 1989-11-06 | 1996-10-14 | Cell Genesys Inc | Fremstilling af proteiner ved homolog rekombination |
GB8927722D0 (en) | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
NZ236819A (en) | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
US5503333A (en) | 1993-06-23 | 1996-04-02 | Laventure; David | Duster extension tube system with dust collecting region and tube cleaner and method of using the same |
US5811252A (en) | 1994-07-07 | 1998-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modified proenzymes as substrates for proteolytic enzymes |
US5955072A (en) | 1994-07-13 | 1999-09-21 | Sankyo Company, Limited | Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide |
US7531325B2 (en) | 1997-04-25 | 2009-05-12 | Sembiosys Genetics Inc. | Method for cleavage of fusion proteins |
US20030207402A1 (en) | 1997-08-22 | 2003-11-06 | Erhard Kopetzki | Autocatalytically activatable zymogenic precursors of proteases and their use |
GB9817909D0 (en) | 1998-08-17 | 1998-10-14 | Zeneca Ltd | DNA constructs |
GB9908458D0 (en) | 1999-04-13 | 1999-06-09 | Queen Mary & Westfield College | Enzyme |
AU4970900A (en) | 1999-05-05 | 2000-11-21 | Genentech Inc. | Elastase variants and substrates |
US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
PT1923068E (pt) * | 1999-09-24 | 2011-07-29 | Proteon Therapeutics Inc | Sistema e métodos para a abertura de condutas biológicas obstruídas |
US7063838B1 (en) | 1999-09-24 | 2006-06-20 | Proteon Therapeutics Llc | Methods for treating an artery or vein in a human subject |
US7351549B2 (en) | 2000-01-24 | 2008-04-01 | Polymun Scientific Immunbiologische Forschung Gmbh | Method for the manufacture of recombinant trypsin |
JP2003523756A (ja) | 2000-02-24 | 2003-08-12 | フィロス インク. | 触媒蛋白質の生成のための改良された方法 |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US20060189941A1 (en) | 2002-01-22 | 2006-08-24 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
JP2007525423A (ja) | 2003-02-20 | 2007-09-06 | プロテオン セラピューティクス,インコーポレーテッド | 生体導管の疾患を治療および予防するための方法 |
US7571008B2 (en) | 2003-08-18 | 2009-08-04 | Medtronic, Inc. | System and apparatus for remote activation of implantable medical devices |
JP2008503712A (ja) * | 2004-06-21 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨関節炎治療の方法及び手段 |
CA2580957A1 (en) | 2004-09-22 | 2006-04-06 | Proteon Therapeutics, Inc. | Methods for the treatment and prevention of diseases of biological conduits |
RU2299070C2 (ru) * | 2005-02-08 | 2007-05-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения заболевания вен и способ ее получения |
US20060193824A1 (en) | 2005-02-28 | 2006-08-31 | Rubin Bruce K | Methods for the treatment of infectious and inflammatory airway diseases |
CN1769424A (zh) * | 2005-09-20 | 2006-05-10 | 浙江大学 | 一种芽孢杆菌菌株及其用途 |
ES2372709T3 (es) * | 2006-07-05 | 2012-01-25 | Catalyst Biosciences, Inc. | Procedimientos de cribado de proteasas y proteasas identificadas por los mismos. |
US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
US7999092B2 (en) * | 2008-04-03 | 2011-08-16 | Hudsonalpha Institute For Biotechnology | Amplicon rescue multiplex polymerase chain reaction for amplification of multiple targets |
-
2008
- 2008-12-03 US US12/327,809 patent/US8501449B2/en active Active
- 2008-12-04 PL PL08861467T patent/PL2229440T3/pl unknown
- 2008-12-04 RU RU2010127232A patent/RU2611200C2/ru active
- 2008-12-04 EP EP13181046.7A patent/EP2666854B1/en active Active
- 2008-12-04 TW TW097147270A patent/TWI577385B/zh not_active IP Right Cessation
- 2008-12-04 US US12/746,509 patent/US9057060B2/en not_active Expired - Fee Related
- 2008-12-04 NZ NZ585866A patent/NZ585866A/xx unknown
- 2008-12-04 PT PT88614672T patent/PT2229440E/pt unknown
- 2008-12-04 RS RS20170443A patent/RS55982B1/sr unknown
- 2008-12-04 RS RS20130514A patent/RS53083B/en unknown
- 2008-12-04 CA CA2707051A patent/CA2707051C/en active Active
- 2008-12-04 KR KR1020167020627A patent/KR101824350B1/ko active IP Right Grant
- 2008-12-04 PT PT131810467T patent/PT2666854T/pt unknown
- 2008-12-04 KR KR1020187002034A patent/KR20180011860A/ko not_active Application Discontinuation
- 2008-12-04 MX MX2010006211A patent/MX2010006211A/es active IP Right Grant
- 2008-12-04 DK DK08861467.2T patent/DK2229440T3/da active
- 2008-12-04 AU AU2008338743A patent/AU2008338743B2/en not_active Ceased
- 2008-12-04 CN CN201811632685.6A patent/CN109893647A/zh active Pending
- 2008-12-04 CN CN201410767370.8A patent/CN104711243B/zh not_active Expired - Fee Related
- 2008-12-04 DK DK13181046.7T patent/DK2666854T3/da active
- 2008-12-04 SI SI200831792A patent/SI2666854T1/sl unknown
- 2008-12-04 ES ES13181046.7T patent/ES2627066T3/es active Active
- 2008-12-04 KR KR1020107014799A patent/KR101732190B1/ko active IP Right Grant
- 2008-12-04 EP EP17150627.2A patent/EP3176262A1/en not_active Withdrawn
- 2008-12-04 WO PCT/US2008/085559 patent/WO2009079220A2/en active Application Filing
- 2008-12-04 NZ NZ601592A patent/NZ601592A/en unknown
- 2008-12-04 TW TW105106918A patent/TWI619726B/zh not_active IP Right Cessation
- 2008-12-04 CN CN200880124812.XA patent/CN101918547B/zh not_active Expired - Fee Related
- 2008-12-04 LT LTEP13181046.7T patent/LT2666854T/lt unknown
- 2008-12-04 BR BRPI0819977-9A patent/BRPI0819977A2/pt not_active Application Discontinuation
- 2008-12-04 ES ES08861467.2T patent/ES2436783T3/es active Active
- 2008-12-04 MX MX2013000540A patent/MX341317B/es unknown
- 2008-12-04 EP EP08861467.2A patent/EP2229440B9/en active Active
- 2008-12-04 PL PL13181046T patent/PL2666854T3/pl unknown
- 2008-12-04 HU HUE13181046A patent/HUE032739T2/en unknown
- 2008-12-04 CN CN201410187187.0A patent/CN103952388B/zh not_active Expired - Fee Related
- 2008-12-04 JP JP2010537075A patent/JP5829808B2/ja not_active Expired - Fee Related
- 2008-12-04 SI SI200831101T patent/SI2229440T1/sl unknown
- 2008-12-05 AR ARP080105302A patent/AR069584A1/es active IP Right Grant
-
2010
- 2010-06-03 IL IL206157A patent/IL206157A/en active IP Right Grant
- 2010-06-24 US US12/823,098 patent/US20150322420A9/en not_active Abandoned
-
2011
- 2011-03-21 HK HK11102770.9A patent/HK1148772A1/xx not_active IP Right Cessation
-
2013
- 2013-06-06 IL IL226771A patent/IL226771A0/en unknown
- 2013-08-02 US US13/957,954 patent/US20130336956A1/en not_active Abandoned
- 2013-11-12 CY CY20131101003T patent/CY1114724T1/el unknown
- 2013-11-27 HR HRP20131135AT patent/HRP20131135T1/hr unknown
-
2014
- 2014-08-21 US US14/465,754 patent/US20150166974A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094887A patent/JP6084653B2/ja not_active Expired - Fee Related
- 2015-05-19 US US14/715,660 patent/US20150329846A1/en not_active Abandoned
- 2015-12-03 US US14/957,765 patent/US20160243205A1/en not_active Abandoned
-
2016
- 2016-05-04 US US15/146,098 patent/US20160319267A1/en not_active Abandoned
-
2017
- 2017-01-25 JP JP2017011160A patent/JP2017104114A/ja active Pending
- 2017-05-19 HR HRP20170755TT patent/HRP20170755T1/hr unknown
- 2017-06-02 CY CY20171100583T patent/CY1118930T1/el unknown
- 2017-10-06 US US15/726,607 patent/US20180273928A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,505 patent/US20190010476A1/en not_active Abandoned
- 2018-01-25 US US15/880,029 patent/US10301612B2/en not_active Expired - Fee Related
- 2018-03-13 US US15/919,814 patent/US10308924B2/en not_active Expired - Fee Related
- 2018-03-13 US US15/919,795 patent/US20190062718A1/en not_active Abandoned
-
2019
- 2019-08-09 US US16/536,814 patent/US20200208132A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114724T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
CY1115082T1 (el) | Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων | |
MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
EA200870391A1 (ru) | Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
EA201000329A1 (ru) | Циклические депсипептиды | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
CY1114075T1 (el) | Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης | |
BR0211761A (pt) | depsipeptìdeos e processos para preparar os mesmos | |
EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
DE602004014145D1 (de) | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen | |
ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
UY29999A1 (es) | "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones" | |
EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
GT200600209A (es) | Tratamiento de enfermedades usando un sistema mejorado de expresion regulada | |
ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone | |
DK1537204T3 (da) | Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller |